Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | MTTP | P55157 | 8/20 | 0.46 |
| ▸ | APOB | P04114 | 6/20 | 0.45 |
| ▸ | SMO | Q99835 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795589 | 0.90 | ALDH1A1 (0.45) | TP53MAPTLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL6794470 | 0.89 | TP53 (0.54) | TP53MAPTLMNAMTTPAPOB | |
| SCHEMBL6789887 | 0.88 | LMNA (0.58) | LMNAMTTPAPOBSMOHTT | |
| SCHEMBL6800205 | 0.88 | TP53 (0.47) | TP53MAPTLMNAMTTPAPOB | |
| SCHEMBL6792997 | 0.87 | TP53 (0.49) | TP53MAPTLMNAMTTPAPOB | |
| SCHEMBL6794575 | 0.84 | MTTP (0.49) | MAPTLMNAMTTPAPOBSMO | |
| SCHEMBL6787479 | 0.83 | AOC3 (0.52) | TP53MAPTLMNAMTTPAPOB | |
| SCHEMBL6794847 | 0.81 | MTTP (0.52) | TP53MTTPAPOBSMOKDM4E | |
| SCHEMBL6789936 | 0.81 | ADAMTS7 (0.49) | MTTPAPOBSMOSMN1; SMN2 | |
| SCHEMBL6795017 | 0.81 | TP53 (0.50) | TP53MAPTLMNAMTTPAPOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | TP53 4865/4885MAPT 4795/4885LMNA 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.